Clinical trial
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate…
NCT00226954 · Stanford University, Other · Terminated
Key facts
| NCT number | NCT00226954 |
|---|---|
| Title | Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer |
| Official title | Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer |
| Lead sponsor | Stanford University, Other |
| Collaborators | Novartis Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Urologic Neoplasms |
| Intervention type | Drug |
| Interventions | zoledronic acid |
| Enrollment | 23 |
| Start date | Mar 1, 2003 |
| Primary completion | Nov 1, 2007 |
| Completion | Feb 1, 2009 |
| First posted | Sep 27, 2005 |
| Last update posted | Mar 18, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: